Mit Magzter GOLD unbegrenztes Potenzial nutzen

Mit Magzter GOLD unbegrenztes Potenzial nutzen

Erhalten Sie unbegrenzten Zugriff auf über 9.000 Zeitschriften, Zeitungen und Premium-Artikel für nur

$149.99
 
$74.99/Jahr

Versuchen GOLD - Frei

Can DPDPA's Research Exemption Power Private Sector Breakthroughs?

Bio Spectrum

|

October 2025

India's Digital Personal Data Protection Act, 2023 (DPDPA), imposes uniform data protection obligations across sectors, significantly affecting healthcare, pharma, and biotech firms due to their use of sensitive personal data. Section 17(2) (b) provides limited exemptions for "research, archiving, or statistical purposes," which some stakeholders interpret as broad immunity.

Can DPDPA's Research Exemption Power Private Sector Breakthroughs?

This article challenges that view, arguing that Indian policy generally restricts exemptions for private, profit-driven research unless a clear public interest is demonstrated. Drawing on parallels with the GDPR, it concludes that the exemption will likely be narrowly construed, and the forthcoming DPDPA Rules are unlikely to support a wide carve-out.

The Digital Personal Data Protection Act, 2023 (DPDPA) is a law that primarily affects and benefits people and organisations that deal with personal data.

From tech giants to hospitals, from law firms to educational boards, the law places clear obligations on all those processing personal data. Healthcare, pharma, and biotech companies are no exception. While much attention has been drawn to how social media companies are affected, the impact on healthcare, pharma, and biotech sectors has not been adequately analysed.

Many such companies believe that the research exemption under Section 17(2)(b) of the DPDPA will save them from onerous compliance. But that belief may be flawed. In this article, we explain why.

The regulatory intent behind Sec. 17(2)(b) of DPDPA

Section 17(2)(b) allows personal data use for research, archiving, or statistics, if not tied to individuals and done per government norms.

It reads as:

- ‘(b) necessary for research, archiving or statistical purposes if the personal data is not to be used to take any decision specific to a Data Principal and such processing is carried on in accordance with such standards as may be prescribed.’

The “standards as may be prescribed” have not yet been prescribed, which means the exemption is not yet live. The rules for the DPDPA will propose standards and give other clarifications regarding the clause.

The direction of India’s public policy

WEITERE GESCHICHTEN VON Bio Spectrum

Bio Spectrum

Bio Spectrum

Building Breakthrough Medical Devices

Dr Ria Khurana founded RNT Health Insights, a Chandigarh-based healthtech startup specialising in Al-assisted diagnostic solutions for the accurate detection of pathologies during endoscopic procedures, in 2022 along with Dr Tanmaya Gulati.

time to read

2 mins

January 2026

Bio Spectrum

Bio Spectrum

Bridging classical epidemiology with modern science

A physician scientist with a MBBS from Lady Hardinge Medical College, (University of Delhi), a post-graduation in Paediatrics and a PhD from All India Institute of Medical Sciences (AIIMS), New Delhi, Prof.Shinjini Bhatnagar served as Professor of Eminence at Translational Health Science and Technology Institute (THSTI) until February 2023 and was subsequently appointed Distinguished Professor at THSTI until May 2025.

time to read

2 mins

January 2026

Bio Spectrum

Bio Spectrum

"AI, Automation & Analytics: A new era of modern microbiology testing!"

Pharmaceutical manufacturing is undergoing a paradigm shift.

time to read

4 mins

January 2026

Bio Spectrum

Bio Spectrum

The CRISPR Moment

CRISPR (clustered regularly interspaced short palindromic repeats) technology is ushering in a new era of gene and cell therapy, offering more precision and potential for treating genetic disorders, cancer, and infectious diseases.

time to read

2 mins

January 2026

Bio Spectrum

Leveraging Microfluidic Technology for mRNA-LNP Manufacturing

Over the past five years, messenger RNA (mRNA) therapeutics have evolved from experimental concepts into lifesaving medicines.

time to read

2 mins

January 2026

Bio Spectrum

Bio Spectrum

Demonstrating India's Vaccine Capabilities

Havisure is India's first and only indigenously developed Hepatitis A vaccine, to address one of the country's most persistent public health challengeswidespread Hepatitis A infections caused by inadequate sanitation and contaminated food and water.

time to read

2 mins

January 2026

Bio Spectrum

Bio Spectrum

Inspiring Future Generations

A PhD in molecular biology from the University of Cambridge, UK, Prof. Gaiti Hasan is a Distinguished Fellow at the National Centre for Biological Sciences (NCBS), Bengaluru.

time to read

2 mins

January 2026

Bio Spectrum

Bio Spectrum

A Landmark for India's Antibiotic Innovation

After three decades of research and hard work, India has led the way with the creation of Nafithromycin, the country's first indigenous antibiotic.

time to read

2 mins

January 2026

Bio Spectrum

Bio Spectrum

"Future vaccine innovation will be integration of R&D, regulatory support and manufacturing”

TechInvention Lifecare Limited, a vaccine focused biotechnology company headquartered in Mumbai, is recognised for its innovative contributions to global healthcare.

time to read

4 mins

January 2026

Bio Spectrum

Bio Spectrum

Telangana: Building India's Most Credible Life Sciences Ecosystem

Telangana's recognition as BioSpectrum India's Best Performing State in Life Sciences 2025 is a timely validation of the direction the state has taken in recent years-one anchored in execution, responsiveness, and a clear understanding of where global life sciences value chains are headed.

time to read

4 mins

January 2026

Listen

Translate

Share

-
+

Change font size